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Abstract
Introduction: Infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha (TNF-α) that has been 
introduced recently for Behçet's disease (BD) patients who were resistant to standard treatment. The aim of this study 
was to analyse the functional changes of Vγ9/Vδ2 T lymphocytes in both active and inactive disease and the effect of 
infliximab on Vγ9/Vδ2 T cell expansion, activation and cytotoxicity.
Methods: We investigated 1) cell expansion, 2) expression of TNFRII receptor, 3) perforin and gamma interferon (IFN) 
content, 4) release of granzyme A (GrA) and 5) phenotype changes, in vitro and in vivo, in Vγ9/Vδ2 T lymphocytes by 
means of fluorescence-activated cell sorter analysis of lymphocyte cultures from patients with active and inactive BD 
and healthy subjects.
Results: Cell expansion, expression of TNFRII, perforin and gamma IFN content and release of granzyme A were 
significantly higher in active patients. In vitro and ex vivo treatment with infliximab resulted in a significant reduction of 
all parameters together with changes in the phenotype of Vγ9/Vδ2 T cells.
Conclusions: All together these data indicate that infliximab is capable of interfering with Vγ9/Vδ2 T cell function in BD 
and although cell culture models cannot reliably predict all potential effects of the drug in vivo, our results present the 
possibility that this drug may find use in a range of immunological disorders, characterized by dysregulated cell-
mediated immunity.
Introduction
Behçet's disease (BD) is a multisystemic inflammatory
disorder characterized mainly by recurrent oral and geni-
tal apthous ulcerations and uveitis. The clinical spectrum
of BD is wide, involving skin, blood vessels, joints, ner-
vous system, lungs and intestines. The treatment of BD is
based for most patients on the combination of corticos-
teroids and immunosuppressive agents. Despite the
improvement obtained with this strategy, relapses and
failure may occur, some patients being also refractory to
all treatments. Infliximab a chimeric monoclonal anti-
body against TNF-α that has been introduced for patients
with Crohn's disease, rheumatoid arthritis, psoriasis,
juvenile chronic arthritis and more recently for BD
patients who were resistant to standard treatment [1,2].
The immunopathogenesis of BD remains unknown, but
it is believed to be T cell-mediated [3-5]. Recently, atten-
tion has been focused on the role of γδ T cells and we
have demonstrated that Vγ9/Vδ2 circulating lympho-
cytes are activated in patients with active disease and
express increased levels of receptors for TNF-α and IL
(interleukin)-12 [6]. Moreover, elevated levels of gran-
zyme A both in the serum and Vγ9/Vδ2 cell supernatants
of active BD patients are present, suggesting a role for this
kind of lymphocytes in the pathogenesis and in the pro-
gression of the disease [7]. In this paper we analysed the
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functional changes of Vγ9/Vδ2 T lymphocytes in both
active and inactive disease and of the effect of infliximab
on Vγ9/Vδ2 cell expansion, activation and cytotoxicity.
Materials and methods
Patients
Thirteen patients with BD (nine males and four females,
mean age 42 ± 24 years), classified according to the Inter-
national Study Group for Behçet's Disease [8] were stud-
ied. The activity of BD was assessed by collecting clinical
symptoms defined according to the BDCAF score [9,10]
that includes the presence of several manifestations of the
disease, by the uveitis scoring system and by the visual
activity measurement [11]. At the time of sampling, dis-
ease was active in six patients and inactive in seven. In
five of the active patients blood for serum and lympho-
cyte studies was obtained before and after the anti-TNF-α
(Infliximab) therapy. All patients were using colchicine (n
= 13), and/or low dose corticosteroids (n = 8). Ten healthy
volunteers (age range 21 to 47, mean 30 ± 8 years) were
enrolled as controls. None of patients or controls were
HIV, CMV, EBV infected. Human studies committee
approval and individual informed consent from each
patient were obtained.
Cell separation and in vitro expansion by Vγ9/Vδ2 T 
lymphocytes
Peripheral blood mononuclear cells (PBMC) were
obtained from each individual by separating heparinized
venous blood on Ficoll (Euroclone, Wetherby, Yorkshire,
UK). The cells were washed in RPMI-1640 medium
(Euroclone), and cultured in 24-well plates (Costar, Cam-
bridge, MA, USA) at a concentration of 5 × 105 cells/ml in
RPMI-1640 supplemented with 10% foetal calf serum
(Euroclone) 20 mM Hepes (Euroclone), 2 mM L-glu-
tamine (Euroclone) and 100 U/ml penicillin/streptomy-
cin (Sigma, St Louis, MO, USA) at 37°C at 0,5% CO2. For
the expansion of Vγ9/Vδ2 T cells, PBMCs were cultured
for 10 days in medium alone or in the presence of 0,5 mM
Dimethylallyl pyrophosphate (DMAPP, Sigma, St Louis).
After 72 hours, cultures were supplemented with a 0,5 ml
medium containing 40 U/ml recombinant human IL-2
(Genzyme, Cambridge, MA, USA). Every 72 h, 0.5 ml
medium was replaced with a 0.5 ml fresh medium con-
taining IL-2. After 10 days, cells were washed three times
in medium, and expansion of Vγ9/Vδ2 T cells was
assessed using a FACScan flow cytometer (Becton Dick-
inson, Mountain View, CA, USA) by using forward scat-
ter/side scatter gating to select the lymphocyte
population for analysis. The Vγ9/Vδ2 T cell expansion
factor (EF) was then calculated as described above [6].
Monoclonal antibody and flow cytometry
Monoclonal antibodies (MOAbs) specific for human sur-
face antigens anti-T cell receptor (TCR) Vδ2 fluorescein
isothiocyanate-labelled (FITC; PharMigen, San Diego,
CA, USA), anti-CD27 phycoerythrin-labelled (PE, Phar-
Migen), anti-CD45RO quantum red (QR, Sigma), anti-
TNF-RII PE (R&D System, Minneapolis, MN, USA) were
used. For the evaluation of intracytoplasmic content of
perforin (Pf) and IFN-γ, 3 × 105 cells were stained with
anti- Vδ2 TCR FITC and, after washing, fixed with 4%
paraformaldehyde (Sigma) for 30 minutes at 4°C. After
two washes with permeabilization buffer (saponine con-
taining) the cells were incubated at 4°C for 45 minutes
with anti perforin Pe antibody (Ancell Corporation, Bay-
port, MN, USA) or with anti-IFN-γ PE (Euroclone). After
washing, the cells were suspended in PBS with 1% foetal
calf serum and data were acquired on a FACScan instru-
ment and analyzed using WinMDI version 2.8 software.
The number of Pf and TNF-RII molecules (MESF;
molecular equivalents of soluble fluorochrome) was cal-
culated by fluorescence-activated cell sorter analysis of
cells stained with saturating amounts of PE labelled anti-
TNF-RII and anti-Pf mAb of known PE/protein ratio and
comparing the staining with a standard curve of micro-
beads labelled with defined numbers of PE molecules
(Quantum Fluorescence Kit, Sigma). The analysis was
done using Quickal Program for MESF Units for Win-
dows.
Esterase assay for GrA
GrA activity was tested using the synthetic substrate N-α-
benzyloxycarbonyl-L-lysine thiobenzyl ester (z-lys-SBzl;
Sigma) as previously described [7]. Briefly, 20 μl of super-
natants (obtained at the 10th day of Vγ9/Vδ2 culture) or
diluited (1:100 in PBS) sera were coincubated with 35 μl 1
mM z-lys-SBzl and 35 μl 1 mM 5,5-dithio-bis-
(2nitrobenzoic acid) (Sigma). After incubation at 37°C for
2 hours and 30 minutes respectively, the absorbance at
405 nm was determined. Esterolytic activity of GrA was
reported as mOD units.
In vitro effect of Infliximab on Vγ9/Vδ2 cultures
In order to examine the effects on Vγ9/Vδ2 expansion,
TNF-RII expression, perforin and IFN-γ content, and
supernatant levels of GrA, Infliximab (Remicade; Cento-
cor Inc., Malvern, PA, USA; Schering Plough SpA, Seg-
rate (Mi), Italy) was added in the medium at a final
concentration of 10, 50 (for 3 days) and 100 μg/ml (for 3
and 10 days).
Effect of Infliximab therapy
Five patients with active disease were treated with Inflix-
imab, 5 mg/Kg, by a two hour infusion, at weeks 0, 2, 4
and the patients observed for a further two hours without
adverse effects. Sampling, for Vγ9/Vδ2 studies, were per-
formed before the start of therapy and at the time of the
second infusion.Accardo-Palumbo et al. Arthritis Research & Therapy 2010, 12:R109
http://arthritis-research.com/content/12/3/R109
Page 3 of 6
Statistics
All values are expressed as mean ± SD. We performed
analysis of significance in Prism (GraphPad, La Jolla, CA,
USA) by the two-tailed t test analysis and by two-way
ANOVA.
Results
Functional changes of Vγ9/Vδ2 T lymphocytes
Cumulative results are shown in Table 1. The EF of Vγ9/
Vδ2 T lymphocytes from active BD patients was signifi-
cantly higher (295 ± 44; P <0.0001) than those obtained
from inactive patients (36 ± 8) and from healthy controls
(30 ± 8). Vγ9/Vδ2 TNF-RII was 10,422 ± 1,694 in active
patients, 4,087 ± 1,671 in inactive patients and 4,512 ±
1,436 in healthy controls. The intracytoplasmic content
of IFN-γ was 40.4 ± 8.2% in Vγ9/Vδ2 standard cultures
from active patients, and 18 ± 7% and 11 ± 4% in inactive
patients and healthy subjects respectively. Intracytoplas-
mic perforin content was 27,581 ± 4,611 in active patients
and, 5,247 ± 1,230 and 4,980 ± 1,110 in inactive patients
and controls respectively.
GrA levels were (818 ± 97 mOD units) significantly
higher in the supernatants obtained from cultures of
active patients than those obtained from inactive patients
(589 ± 21) and controls (550 ± 30). Staining of PBMC cul-
tures with antibodies to Vδ2-TCR, CD45RO and CD27
identified four subsets of Vγ9/Vδ2 T cells (Table 2): 1) a
subset with a naive CD45RO- CD27+ phenotype, 2) a sub-
set with a memory CD45RO+ CD27+ phenotype; 3) a sub-
set with a effector CD45RO+ CD27- phenotype and 4) a
subset with a terminally differentiated cytotoxic
CD45RO-  CD27-  phenotype. In active patients we
observed that the phenotype of Vγ9/Vδ2 T cells is mainly
composed of CD45RO+CD27- effector cells (57 ± 13%)
and that there is, also, evidence of CD45RO-CD27- termi-
nally differentiated cytotoxic cells (20 ± 6%). In contrast,
in Vγ9/Vδ2 cultures of inactive patients as well as of nor-
mal controls, we found mainly the phenotypes
CD45RO+CD27+ (47 ± 9 and 49 ± 9%) and CD45RO-
CD27+ (24 ± 7 and 20 ± 8%) that are characteristics of
memory and naive cells, respectively.
In vitro studies with Infliximab
The addition of Infliximab to the cultures from active
patients determined a significant time and dose depen-
dent inhibition of cell expansion (Figure 1a) and a signifi-
c a n t  d e c r e a s e  o f  T N F - R I I  e x p r e s s i o n  ( F i g u r e  1 b ) .  I n
particular, the mean EF was 295 ± 43.4 in untreated cul-
tures and 50 ± 23 in culture with the highest infliximab
concentration (P < 0.001). TNFRII MESF was 10,500 ±
1,707 in untreated culture and 4,576 ± 845 (Infliximab 10
μg/ml for 3 days; P < 0.05), 3,466 ± 394 (Infliximab 50 μg/
ml for 3 days; P < 0.01) and 833 ± 165 (Infliximab 100 μg/
ml for 10 days, P < 0.001) respectively after exposure to
infliximab. IFN-γ in untreated cultures was 40.4 ± 8.25%.
In the presence of Infliximab we found values of 10.5 ±
3.51% (Infliximab 10 μg/ml for 3 days; P < 0.01), 7.2 ±
1.8% (Infliximab 50 μg/ml for 3 days; P < 0.001) and 5.5 ±
1.7% (Infliximab 100 μg/ml for 10 days; P < 0.001) (Figure
1c).
A significant reduction of cell perforin content (7,040 ±
985 vs 27,573 ± 4,590, P < 0.001) was also observed after
infliximab (50 μg/ml for 10 days) (not shown) exposure
together with a decrease of granzyme release in the
supernatants (Figure 1d); in standard cultures the GrA
levels were 818 ± 91.6 mOD, in the presence of Infliximab
the levels were 538 ± 72 (10 μg/ml for 3 days; P < 0.05),
518 ± 69 mOD (50 μg/ml for 3 days; P < 0.05) and 240 ±
25 mOD (100 μg/ml for 10 days; P < 0.01). The Vγ9/Vδ2
cells from active patients cultured in presence of Inflix-
imab (50 μg/ml) shown mainly the phenotype of memory
(75 ± 15%) and naive (21 ± 3%) cells rather than those of
effector (1.76 ± 1.28%) and cytotoxic (0.3 ± 0.21%) cells
(Figure 2).
In vivo treatment with Infliximab
Five patients with active disease were infused with 5 mg/
Kg of Infliximab, and Vγ9/Vδ2 studies were performed
before and after therapy (Table 3). A significant EF differ-
Table 1: Functional changes of Vγ9/Vδ 2 T lymphocytes in BD patients and controls
Active BD Inactive BD Controls P
EF of Vγ9/Vδ2 295 ± 44 36 ± 8 30 ± 8 < 0.0001
Vγ9/Vδ 2 TNF-RII 10,422 ± 1,694 4,087 ± 1.671 4,512 ± 1436 < 0.0001
IFN-γ (% of Vγ9/Vδ 2) 40.4 ± 8.2 18 ± 7 11 ± 4 < 0.001
Perforin (mOD units) 27,581 ± 4.611 5,247 ± 1,230 4,980 ± 1,110 < 0.001
Granzyme A (mOD 
units)
818 ± 97 589 ± 21 550 ± 30 < 0.05
BD: Behçet's disease; EF: Expansion factor.Accardo-Palumbo et al. Arthritis Research & Therapy 2010, 12:R109
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ence was found in the Vγ9/Vδ2 cultures from patients
before (256 ± 90) and after (80 ± 44; P < 0.01) Infliximab
therapy. Serum GrA levels were 715 ± 174 mOD and 207
± 72 mOD (P < 0.001) respectively. After therapy, the cells
showed the phenotype of memory (61 ± 11%) and naive
(21 ± 3%) cells.
Discussion
The immunopathogenesis of BD is unknown. Various
micro-organisms such as streptococci and herpes simplex
virus have been implicated in the pathogenesis in geneti-
cally susceptible HLA-B51+ individuals [12,13].
There is evidence of immunological dysregulation,
including neutrophil hyperfunction [14,15], autoimmune
manifestations [16] and several phenotypic and func-
tional lymphocyte abnormalities, most of the immuno-
logical studies suggesting a central role for T cells in the
pathogenesis of this disease [17]. Cytotoxic T cells are
considered to play a role in the development of disease.
Recent studies [18,19] and our own [6] point also for a
role of activated Vγ9/Vδ2 T lymphocytes in the progres-
sion and probably in the pathogenesis of the disease.
The treatment of BD comprises mainly systemic corti-
costeroids for most manifestations of BD. Supplemental
therapy with other immunomodulatory agents is often
necessary to control serious manifestations such as
uveitis and meningoencephalitis and to reduce the inci-
dence of long-term steroid toxicity. Drugs usually used in
BD such as glucocorticoids, pentoxifylline and
cyclosporine have been demonstrated to modulate
peripheral blood gamma delta T lymphocytes [20-22].
The role of TNF-blocking agents on gamma delta T
lymphocyte functions has not yet been investigated. In
BD, increased serum levels of TNF-α and soluble TNF-
RII has been observed during the active stage of disease
suggesting a role for TNF-α in the pathogenesis [23-25].
In addition, TNF-α, that has been reported also to be pro-
Table 2: Subpopulations of Vγ9/Vδ 2 T lymphocytes in BD patients and controls
Active BD Inactive BD Controls P
CD45RO-CD27+ (%) 7.5 ± 2.25 24 ± 7 28 ± 8 < 0.0001
CD45RO+CD27+ (%) 11 ± 6.44 47 ± 9 49 ± 9 < 0.0001
CD45RO+CD27- (%) 57 ± 13 17.8 ± 9.7 19.2 ± 6.7 < 0.001
CD45RO-CD27- (%) 20 ± 6 8.6 ± 3.8 5.5 ± 5.5 < 0.001
BD, Behçet's disease.
Figure 1 Effects of in vitro addition of Infliximab (10, 50 and 100 
μg/ml) to the cultures from active patients. (a) Expansion of Vγ9Vδ2 
T lymphocytes (%); (b) TNF-RII (MESF); (c) IFN-γ content (%) and (d) 
granzyme release (mOD).
Figure 2 Percentage of Vγ9/Vδ2 cells isolated from active pa-
tients cultured in presence of Infliximab (50 μg/ml). (a) Effector 
CD45RO+CD27-; (b) Cytotoxic CD45RO-CD27-; (c) Memory 
CD45RO+CD27+; naive CD45RO-CD27+.Accardo-Palumbo et al. Arthritis Research & Therapy 2010, 12:R109
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duced by γδ T cells, might stimulate the TNF receptor
bearing γδ T cells, in an autocrine or paracrine manner or
both, to proliferate [26,27].
In this study we investigated the functional changes of
Vγ9/Vδ2 T lymphocytes in both active and inactive
Behçet's disease and the effect of Infliximab on Vγ9/Vδ2
T cell expansion, activation and cytotoxicity.
Infliximab is a high affinity monoclonal anti TNF-α
antibody that has been introduced for Crohn's disease
and rheumatoid arthritis treatment in patients who are
resistant to standard therapy. Our previous studies dem-
onstrated a complete remission of all disease manifesta-
tions in BD patients with ocular involvement and cerebral
vasculitis [1,2].
Infliximab interferes with Vγ9/Vδ2 T cell functions. In
particular, in vitro and in vivo studies demonstrated that
this drug was able to suppress the Vγ9/Vδ2 T cell expan-
sion and activation (TNF-RII expression and IFN-γ pro-
duction) induced by DMAPP. Infliximab interferes also
with the potential cytotoxic activity of these cells that we
evaluated through the expression of the cytoplasmic
granule-associated molecules perforin and the GrA
release in the medium of cultures.
In this paper we did not study the phenotype of circu-
lating Vγ9/Vδ2 T lymphocytes being our cytofluorimet-
ric analysis not sensitive enough to measure membrane
antigens in a relatively low number of cells. Although
these preliminary observations have to be properly
defined, after phosphoantigen stimulation, however, we
observed frequently that the Vγ9/Vδ2 subpopulation was
mainly composed by effector cells in active patients and
by memory cells in inactive patients and controls. After in
vitro exposure to Infliximab, there was a lack of effector
cells, suggesting that this drug might block the lineage
pattern of differentiation (naive → memory → effector →
terminally differentiated cells), as a consequence of
expansion and activation inhibition.
Conclusions
Our observations of disease-specific changes in Vγ9/Vδ2
T cell functions are consistent with the hypothesis that
these cells play a role in the pathogenesis of BD. Despite
the relatively low number of patients enrolled, data col-
lected in this study point also to a critical role in the regu-
lation of cellular activation and function of Vγ9/Vδ2 T
cells by Infliximab and lead to encourage the possibility
that this drug may find widespread use in the treatment
of BD.
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